# US 2024/0199693 A1 · Heptapeptide amides for use in the treatment of hmgb1-dependent diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199693 A1
- Document ID: US20240199693A1
- Status: Published application
- Kind: A1
- Application number: 18/287,512
- Filed: 2022-04-14
- Published: 2024-06-20
- Earliest claimed: 2021-04-22
- Assignees: Federal State Budgetary Institution Scientific Center of Biomedical Technologies of Federal Medical
- Applicants: Federal State Budgetary Institution Scientific Center of Biomedical Technologies of Federal Medical
- Inventors: Vladislav Nikolaevich KARKISCHENKO; Veronika Igorevna SKVORTSOVA; Igor Anatolievich POMYTKIN; Nikolai Nikolaevich KARKISCHENKO
- Web page: https://patentgrep.com/patent/US20240199693A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound of formula (I): where Z is (II) in which R1 and R2 are identical or different and are hydrogen or a lower alkyl chain having up to 4 carbon atoms or a pharmaceutically acceptable salt thereof. Further, the present invention relates to pharmaceutical compositions or dependent inflammatory or autoimmune disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, periodontitis, allergic rhinitis, chronic rhinosinusitis without nasal polyps, chronic rhinosinusitis with nasal polyps, pneumonia, chronic obstructive pulmonary disease, asthma, acute adult respiratory syndrome, diabetic macroangiopathy, diabetic coronary artery disease, peripheral arterial disease, diabetic cerebrovascular disease, diabetic microangiopathy, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic foot ulceration, colitis, inflammatory bowel disease, and ocular disease. Preferably, the pharmaceutically acceptable salt is acetate.

## Claims

### Claim 1

A compound of formula (I):
H-Tyr-D-Ala-Gly-Phe-Leu-Arg-Arg-Z (I)
where Z is
in which R1 and R2 are identical or different and are hydrogen or a lower alkyl chain having up to 4 carbon atoms or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein said compound is selected from the group consisting of H-Tyr-D-Ala-Gly-Phe-Leu-Arg-Arg-NH2 acetate, H-Tyr-D-Ala-Gly-Phe-Leu-Arg-Arg-NHC2H5 acetate, H-Tyr-D-Ala-Gly-Phe-Leu-Arg-Arg-NHC4H9 acetate, and H-Tyr-D-Ala-Gly-Phe-Leu-Arg-Arg-N(CH3)2 acetate.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein said compound is H-Tyr-D-Ala-Gly-Phe-Leu-Arg-Arg-NH2 acetate.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable excipient.

### Claim 5 (depends on 1)

A method of administering a medicament comprising the compound according to claim 1.

### Claim 6 (depends on 1)

A method comprising the step of administering the compound according to claim 1 in the treatment of a HMGB1-dependent inflammatory or autoimmune disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, periodontitis, allergic rhinitis, chronic rhinosinusitis without nasal polyps, chronic rhino sinusitis with nasal polyps, pneumonia, chronic obstructive pulmonary disease, asthma, acute adult respiratory syndrome, diabetic macroangiopathy, diabetic coronary artery disease, peripheral arterial disease, diabetic cerebrovascular disease, diabetic microangiopathy, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic foot ulceration, colitis, inflammatory bowel disease, and ocular disease.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein the pharmaceutically acceptable salt is acetate.
